Trial Profile
First-line randomized, open, controlled clinical trial of EP regimen with sequential apatinib in patients with extensive stage small cell lung cancer
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Jan 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 10 Jan 2017 New trial record